JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
Volume 17, Issue 2 (2025)
Iran J War Public Health 2025, 17(2): 183-189 |
Back to browse issues page
Article Type:
Subject:
Ethics code: 33 in 23/10/2024
History
Received: 2025/05/6 | Accepted: 2025/06/26 | Published: 2025/07/4
Received: 2025/05/6 | Accepted: 2025/06/26 | Published: 2025/07/4
How to cite this article
Abbas E, Rasheed S, Naser L, Hassan E, Bader R. CCL20 Serum Levels as a Biomarker for Psoriasis Severity and Disease-Related Comorbidities. Iran J War Public Health 2025; 17 (2) :183-189
URL: http://ijwph.ir/article-1-1604-en.html
URL: http://ijwph.ir/article-1-1604-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Pathology and Forensic Medicine, Faculty of Medicine, University of Kufa, Najaf, Iraq
2- Department of Medical Microbiology, Faculty of Medicine, University of Kufa, Najaf, Iraq
3- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
2- Department of Medical Microbiology, Faculty of Medicine, University of Kufa, Najaf, Iraq
3- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
Abstract (263 Views)
Aims: Psoriasis is a long-lasting inflammatory skin disease associated with immune system dysregulation and systemic complications. Chemokines play a crucial role in monocyte recruitment and have been linked to the development of various autoimmune conditions. However, the relationship between chemokines and psoriasis severity, as well as their association with disease complications, remains unclear. This study aimed to propose that monitoring serum CCL20 levels in patients with psoriasis may provide valuable insights into disease severity and its associated complications.
Instrument & Methods: This cross-sectional study was conducted on psoriasis patients. Serum CCL20 levels were measured using an enzyme-linked immunosorbent assay. The Psoriasis Area and Severity Index was used to assess disease severity, and information on comorbidities was collected. Statistical analyses were performed to determine associations between CCL20 levels, PASI scores, and complications.
Findings: The mean serum CCL20 levels in psoriasis patients were 112.14 ±8.72ng/L, with range values from 42.89 to 293.50. The mean CCL20 level was higher in mild disease (207.96±13.88) compared to 132.68±15.76 for the moderate group and 78.31±6.48 for the severe group (p=0.0001). The mean serum CCL20 levels were significantly higher in patients with metabolic syndrome (p=0.001), while the mean serum CCL20 levels were significantly lower in psoriatic patients with psoriatic arthritis compared to those without (57.63±8.05 versus 123.82±9.80, p=0.003).
Conclusion: There is an inverse relationship between serum CCL20 levels and the severity of psoriasis, and serum CCL20 levels are significantly associated with metabolic syndrome among psoriatic patients.
Instrument & Methods: This cross-sectional study was conducted on psoriasis patients. Serum CCL20 levels were measured using an enzyme-linked immunosorbent assay. The Psoriasis Area and Severity Index was used to assess disease severity, and information on comorbidities was collected. Statistical analyses were performed to determine associations between CCL20 levels, PASI scores, and complications.
Findings: The mean serum CCL20 levels in psoriasis patients were 112.14 ±8.72ng/L, with range values from 42.89 to 293.50. The mean CCL20 level was higher in mild disease (207.96±13.88) compared to 132.68±15.76 for the moderate group and 78.31±6.48 for the severe group (p=0.0001). The mean serum CCL20 levels were significantly higher in patients with metabolic syndrome (p=0.001), while the mean serum CCL20 levels were significantly lower in psoriatic patients with psoriatic arthritis compared to those without (57.63±8.05 versus 123.82±9.80, p=0.003).
Conclusion: There is an inverse relationship between serum CCL20 levels and the severity of psoriasis, and serum CCL20 levels are significantly associated with metabolic syndrome among psoriatic patients.
Keywords:
References
1. Boehncke WH. Etiology and pathogenesis of psoriasis. Rheum Dis Clin North Am. 2015;41(4):665-75. [Link] [DOI:10.1016/j.rdc.2015.07.013]
2. Samotij D, Nedoszytko B, Bartosińska J, Batycka-Baran A, Czajkowski R, Dobrucki IT, et al. Pathogenesis of psoriasis in the "omic" era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances. Postepy Dermatol Alergol. 2020;37(2):135-53. [Link] [DOI:10.5114/ada.2020.94832]
3. Li Q, Chandran V, Tsoi L, O'Rielly D, Nair RP, Gladman D, et al. Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV). Sci Rep. 2020;10(1):4925. [Link] [DOI:10.1038/s41598-020-61981-5]
4. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-50. [Link] [DOI:10.1016/j.jaad.2013.12.036]
5. Ebtihal CA, Ali AM, Muhsin AA, Alaa HAC. Cytokine serum level association with superantigen production by staphylococcus aureus in psoriasis vulgaris. Res J Pharm Biol Chem Sci. 2016;7(4):172. [Link]
6. Mohammad AR, Shnaien AA, Alabsawy SK, Hassan ES. Protective effect of ipragliflozin in acute brain injury induced by endotoxemia in mice. Iran J War Public Health. 2023;15(3):225-31. [Link] [DOI:10.58209/ijwph.15.3.225]
7. Abd Uljaleel AQ, Hassan ES, Mohammad AR, Hadi NR. Protective effect of dulaglutide on lung injury in endotoxemia mouse model. Iran J War Public Health. 2023;15(1):35-42. [Link]
8. Najm NA, Hassan ES. Ipragliflozin protect from acute pulmonary injury induced by endotoxemia in mouse model via NF-KB pathway. Health Biotechnol Biopharm. 2024;7(4):98-113. [Link]
9. Ghafil FA, Hassan ES, Aziz ND, Salim MM, Majeed SA, Rasheed SMH, et al. Cardioprotective potential of celastrol in sepsis-induced cardiotoxicity; Mouse model of endotoxemia. Iran J War Public Health. 2023;15(4):361-7. [Link]
10. Shnaien AA, Mohammad AR, Hassan ES. Neuroprotective effect of semaglutide in endotoxemia mouse model. Iran J War Public Health. 2023;15(2):199-205. [Link] [DOI:10.58209/ijwph.15.3.225]
11. Mohammad AR, Hassan ES, Majeed SA. PI3K/AKT and STAT3 pathways mediate the neuroprotective effect of dasatinib from acute cerebral injury in endotoxemic mice. Res Pharm Sci. 2024;19(1):64-72. [Link] [DOI:10.4103/1735-5362.394821]
12. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res. 2010;86(2):192-201. [Link] [DOI:10.1093/cvr/cvp391]
13. Elnabawi YA, Garshick MS, Tawil M, Barrett TJ, Fisher EA, Lo Sicco K, et al. CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. J Am Acad Dermatol. 2021;84(4):913-20. [Link] [DOI:10.1016/j.jaad.2020.10.094]
14. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175-83. [Link] [DOI:10.1038/jid.2009.65]
15. Shi ZR, Mabuchi T, Riutta SJ, Wu X, Peterson FC, Volkman BF, et al. The chemokine, CCL20, and its receptor, CCR6, in the pathogenesis and treatment of psoriasis and psoriatic arthritis. J Psoriasis Psoriatic Arthritis. 2023;8(3):107-17. [Link] [DOI:10.1177/24755303231159106]
16. Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81. [Link] [DOI:10.1038/s41419-022-04523-3]
17. Frick VO, Rubie C, Keilholz U, Ghadjar P. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. World J Gastroenterol. 2016;22(2):833. [Link] [DOI:10.3748/wjg.v22.i2.833]
18. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis-current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164-91.. [Link] [DOI:10.1007/s12016-024-08991-7]
19. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-63. [Link] [DOI:10.1016/S0140-6736(03)15268-3]
20. Strober B, Ryan C, Van De Kerkhof P, Van Der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117-22. [Link] [DOI:10.1016/j.jaad.2019.08.026]
21. Alizadeh N, Azimi SZ, Hoseinzadeh S. Body mass index and severity of psoriasis: A cross-sectional study. Iran J Dermatol. 2021;24:46-52. [Link]
22. Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1):41-55. [Link] [DOI:10.1016/j.det.2014.09.004]
23. Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1):58. [Link] [DOI:10.3390/ijms19010058]
24. Brunner PM, Suárez-Fariñas M, He H, Malik K, Wen HC, Gonzalez J, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707. [Link] [DOI:10.1038/s41598-017-09207-z]
25. Furue K, Ito T, Tanaka Y, Yumine A, Hashimoto-Hachiya A, Takemura M, et al. Cyto/chemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon. J Dermatol Sci. 2019;94(1):244-51. [Link] [DOI:10.1016/j.jdermsci.2019.04.002]
26. Purzycka-Bohdan D, Nedoszytko B, Zabłotna M, Gleń J, Szczerkowska-Dobosz A, Nowicki RJ. Chemokine profile in psoriasis patients in correlation with disease severity and pruritus. Int J Mol Sci. 2022;23(21):13330. [Link] [DOI:10.3390/ijms232113330]
27. Babaie F, Omraninava M, Gorabi AM, Khosrojerdi A, Aslani S, Yazdchi A, et al. Etiopathogenesis of psoriasis from genetic perspective: An updated review. Curr Genomics. 2022;23(3):163-74. [Link] [DOI:10.2174/1389202923666220527111037]
28. Tourniaire F, Romier-Crouzet B, Lee JH, Marcotorchino J, Gouranton E, Salles J, et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-κB. PLoS One. 2013;8(6):e66515. [Link] [DOI:10.1371/journal.pone.0066515]
29. Burke SJ, Karlstad MD, Regal KM, Sparer TE, Lu D, Elks CM, et al. CCL20 is elevated during obesity and differentially regulated by NF-κB subunits in pancreatic β-cells. Biochim Biophys Acta. 2015;1849(6):637-52. [Link] [DOI:10.1016/j.bbagrm.2015.03.007]
30. Maaniitty E, Jalkanen J, Sinisilta S, Gunn J, Vasankari T, Biancari F, et al. Differential circulating cytokine profiles in acute coronary syndrome versus stable coronary artery disease. Sci Rep. 2024;14(1):17269. [Link] [DOI:10.1038/s41598-024-68333-7]
31. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399-409. [Link] [DOI:10.1038/nrcardio.2009.55]
32. Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P. Managing the patient with psoriasis and metabolic comorbidities. Am J Clin Dermatol. 2024;25(4):527-40. [Link] [DOI:10.1007/s40257-024-00857-0]
33. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373-83. [Link] [DOI:10.1038/jid.2009.399]
34. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: Mechanism and pathological relevance in psoriasis. J Immunol. 2008;181(7):4733-41. [Link] [DOI:10.4049/jimmunol.181.7.4733]
35. Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. [Link] [DOI:10.1038/ncomms6621]